ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Jiangsu HengRui Medicine Co., Ltd. clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,065 studies whose lead sponsor is Jiangsu HengRui Medicine Co., Ltd. or one of 11 companies grouped under it. 306 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 19, 2026.

Our grouping of 13 registry names, not the registry’s. See them and correct one ↓

Compare Jiangsu HengRui Medicine with Bristol-Myers Squibb and Hoffmann-La Roche →

Pipeline: 156 programs

Each counted once: 147 with a study Jiangsu HengRui Medicine Co., Ltd. leads registered in the last two years, 9 more from Jiangsu HengRui Medicine Co., Ltd.'s own pipeline.

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4 (approved, new studies)
  • Named by Jiangsu HengRui Medicine Co., Ltd. only (no registered study yet; not in the 156)

The 5 of 51 with the most live studies.

Program
adebrelimabSHR1316Phase 3 · 38 live · Carcinoma, Non-Small-Cell Lung · primary completion Dec 2026☆ Track
trastuzumab rezetecanPhase 3 · 32 live · Breast Neoplasms · primary completion Dec 2026☆ Track
Anti-CTLA-4 Monoclonal Antibody SHR-8068SHR8068Phase 3 · 15 live · Carcinoma, Non-Small-Cell Lung · primary completion Jul 2027☆ Track
ribupatideHRS9531Phase 3 · Jiangsu HengRui Medicine Co., Ltd.: Registration · 14 live · Obesity · primary completion Dec 2026☆ Track
notiretatug rezetecanPhase 3 · Jiangsu HengRui Medicine Co., Ltd.: Phase 3 · 14 live · Urinary Bladder Neoplasms · primary completion Dec 2026☆ Track

46 more in phase 3 — sign in to see them all, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Jiangsu HengRui Medicine Co., Ltd.’s own registered studies; “Jiangsu HengRui Medicine Co., Ltd. says” is its pipeline, which lists phases by indication. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

Licenses and deals

2 of Jiangsu HengRui Medicine’s programs have a dated deal behind them: 2 licensed out. Each from the companies’ own releases and filings, linked; the registry does not record them.

Licensed out 2

What it is testing

The drugs Jiangsu HengRui Medicine Co., Ltd.’s studies test, most open studies first — 168 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 20 more

The first 30 of 168; every drug is on its own page, and each page lists its sponsors.

Coming up

130 of Jiangsu HengRui Medicine Co., Ltd.’s studies under way reach primary completion within a year, 27 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. 4N’26
  2. 41D
  3. 5J’27
  4. 10F
  5. 14M
  6. 12A
  7. 6M
  8. 11J
  9. 5J
  10. 4A
  11. 6S
  12. 7O
  13. 5N

The 12 nearest

Show 7 more

Add all 130 to your calendar (.ics) → With an account.

What changed recently

From the registry's own updates since Oct 20, 2026.

Started recruiting10

Show 5 more

Newly registered12

Show 7 more

All 1,065 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now30629%Recruiting 230 · Not yet recruiting 72 · Enrolling by invitation 4
  • Under way, not recruiting777%
  • Completed47545%
  • Stopped early535%Terminated 42 · Withdrawn 8 · Suspended 3
  • Status unknown or other15414%

Phase

Where

  • China950
  • Australia48
  • United States16
  • Poland8
  • Korea, Republic of7
  • Ukraine5

Over the years

  1. 09
  2. 10
  3. 11
  4. 12
  5. 13
  6. 14
  7. 15
  8. 16
  9. 17
  10. 18
  11. 19
  12. 20
  13. 21
  14. 22
  15. 23
  16. 24
  17. 16225
  18. 14726

By the year each study started. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Jiangsu HengRui Medicine Co., Ltd.

  • Jiangsu HengRui Medicine Co., Ltd.
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    573 studies
  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    104 studies →
  • Shandong Suncadia Medicine Co., Ltd.
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    87 studies →
  • Fujian Shengdi Pharmaceutical Co., Ltd.
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    66 studies →
  • Shanghai Hengrui Pharmaceutical Co., Ltd.
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    61 studies →
  • Guangdong Hengrui Pharmaceutical Co., Ltd
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    59 studies →
  • Atridia Pty Ltd.
    Regional office
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    36 studies →
  • Beijing Suncadia Pharmaceuticals Co., Ltd
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    25 studies →
  • Chengdu Suncadia Medicine Co., Ltd.
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    24 studies →
  • Reistone Biopharma Company Limited
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    17 studies →
  • Shanghai Shengdi Pharmaceutical Co., Ltd
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    9 studies →
  • Jiangsu Hengrui Pharmaceutical Co., Ltd.
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    2 studies
  • Hengrui Therapeutics, Inc.
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    2 studies →

Focus areas

Conditions Jiangsu HengRui Medicine Co., Ltd. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,065. Browse all 1,065 →